Drug Profile
Research programme: Parkinson's disease therapeutics - Alectos Therapeutics
Latest Information Update: 18 Apr 2023
Price :
$50
*
At a glance
- Originator Alectos Therapeutics; Simon Fraser University
- Class Antiparkinsonians; Small molecules
- Mechanism of Action Glucosylceramidase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Parkinson's disease
Most Recent Events
- 18 Apr 2023 Early research is ongoing Canada (Alectos Therapeutics pipeline, April 2023)
- 28 Mar 2020 No recent reports of development identified for research development in Parkinson's-disease in Canada
- 11 Feb 2016 Early research in Parkinson's disease in Canada before February 2016 (Alectos Therapeutics pipeline, August 2017)